Departed
Nelson Cabatuan
Chief Financial Officer
LEXX ·
Lexaria Bioscience Corp.
replacing Lexaria’s former CFO, Nelson Cabatuan who resigned effective July 15, 2024
Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 3601–3650 of 18397
replacing Lexaria’s former CFO, Nelson Cabatuan who resigned effective July 15, 2024
Richard Christopher, the Company’s Chief Executive Officer who assumed the responsibilities as the Company’s principal financial officer on an interim basis, relinquished those responsibilities to Mr. Shankman.
Effective October 1, 2024, Michael Shankman, age 64, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.
the Board has appointed J.K. Symancyk to succeed Ms. Drosos as Chief Executive Officer and join the Board as of the Transition Date.
Virginia “Gina” C. Drosos is planning to retire as Chief Executive Officer and as a member of the Board of Directors of the Company (the “Board”), effective November 4, 2024
On October 1, 2024, the Company announced that Jeffrey Knudson will step down from his role as Chief Financial Officer of the Company, effective November 8, 2024, to pursue an opportunity with a private company outside of the healthcare staffing industry.
On October 1, 2024, the Company also announced that Thomas A. George, Senior Vice President, Finance and Chief Financial Officer, will be leaving the Company as part of his planned retirement.
On October 1, 2024, Genesco Inc. (the “Company”) announced the appointment of Cassandra “Sandra” Harris as Senior Vice President, Finance and Chief Financial Officer of the Company, effective October 7, 2024
the Board of Directors (the “Board”) of the Company named Preston D. Wigner, Senior Vice President, as Chairman of the Board (“Chairman”), President and Chief Executive Officer of the Company (the “Appointment”), effective October 1, 2024
George C. Freeman, III, will retire as Chairman, President and Chief Executive Officer and as a member of the Board on the Effective Date
notified the Boards of Directors of the Company, TBI and the Bank of his decision to retire from the Boards of Directors of the Company, TBI and the Bank, and as President of the Company, President and Chief Executive Officer of TBI, and President and Chief Executive Officer of the Bank in 2025
appoint Mr. A. Haag Sherman to serve as President of the Company, Chief Executive Officer of TBI and Chief Executive Officer of the Bank, effective upon the termination of employment of Mr. Howard
The Company's Board of Directors formally appointed Mr. Broos as the Company's Interim Chief Financial Officer, effective immediately.
Wade King's departure from the role of Chief Financial Officer.
Also, on September 30, 2024, the Board appointed Richard A. Wurster to succeed Mr. Bettinger as CEO, effective as of January 1, 2025 (the “Transition Date”).
Kelly Steckelberg will continue to serve as the Company’s Chief Financial Officer until the Effective Date, upon which time she will transition to an advisory role.
the Company announced the appointment of Michelle Chang as the Company’s Chief Financial Officer, effective on or about October 7, 2024
the officers of Old BlackRock immediately prior to the Merger Effective Time became the officers of New BlackRock.
the officers of Old BlackRock immediately prior to the Merger Effective Time became the officers of New BlackRock.
Laurence Fink Chief Executive Officer
Martin Small Chief Financial Officer and Senior Managing Director
On October 1, 2024 Opendoor Technologies Inc. (the “Company”) announced the appointment of Selim F. Freiha as the Chief Financial Officer of the Company effective as of November 4, 2024
each of Hardeep Gulati, Laurence Goldberg, Maneet S. Saroya, Betty Hung, Gwen Reinke, Zach Levitt, Judy Cotte, Amy McIntosh, Barbara Byrne and Ronald D. McCray resigned from the Board of Directors
On October 1, 2024, the Board of Directors (the “Board”) of LPL Financial Holdings Inc. (the “Company”) terminated Dan H. Arnold, President and Chief Executive Officer of the Company, in the course of an investigation conducted by outside counsel that determined that Mr. Arnold made statements to employees that violated the Company’s Code of Conduct.
The Company also announced that Rich Steinmeier, currently the Managing Director, Chief Growth Officer of LPL Financial LLC, a subsidiary of the Company (“LPL Financial”), has been appointed as the Company’s Interim Chief Executive Officer, effective immediately.
On September 30, 2024, Verde Clean Fuels, Inc. (the “Company”) appointed George W. Burdette III (“Mr. Burdette”) as Chief Financial Officer of the Company
the Board announced that it had appointed (i) Mr. Frates to serve as the Company’s Executive Vice President and Chief Financial Officer, effective October 21, 2024
On September 25, 2024, the board of directors (the “ Board ”) of Windtree Therapeutics, Inc. (the “ Company ”) appointed Jamie McAndrew as Senior Vice President and Chief Financial Officer, effective as of September 25, 2024 (the “ Effective Date ”).
Ryan Barretto was appointed as Chief Executive Officer of the Company, effective October 1, 2024
On September 30, 2024, the Board of Directors (the “Board”) of BrightSphere Investment Group Inc. (the “Company”) appointed Kelly Young as the Company’s President and Chief Executive Officer and as a Director of the Company, each effective as of January 1, 2025.
On September 25, 2024, Jeff J. Kaminski notified KB Home of his intention to retire as Executive Vice President and Chief Financial Officer in early 2025, after more than 14 years of service.
On September 30, 2024, Vor Biopharma Inc. (the “Company”) announced that the board of directors (the “Board”) has appointed Han Choi, M.D., LL.M., as Chief Financial Officer of the Company, effective as of September 30, 2024 (the “Effective Date”).
Ms. Rexroad will succeed Robert Bowers in his role as Executive Vice President & Chief Financial & Administrative Officer.
The board of directors of Piedmont Office Realty Trust, Inc. (the “Company”) has appointed Sherry Rexroad as Chief Financial Officer of the Company, effective November 8, 2024.
the board of managers of the Company (the “Board”) has appointed Ms. Gloria Nelund, the Company’s Chief Executive Officer and President, to also temporarily serve as the Company’s interim Chief Financial Officer.
Mark A. Tipton resigned from his position as Chief Financial Officer of TriLinc Global Impact Fund, LLC
On September 25, 2024, the board of directors (the “ Board ”) of Lazydays Holdings, Inc., a Delaware corporation (the “ Company ”), appointed Jeff Huddleston, age 50, as Interim Chief Financial Officer of the Company.
On September 25, 2024, Ann C. Beemish, the Chief Financial Officer of MediaCo Holding Inc. (the “Company”), resigned as an officer of the Company, effective September 30, 2024.
On September 26, 2024, the Board of Directors (the “Board”) of the Company appointed Debra DeFelice, age 55, as the Company’s Chief Financial Officer and Treasurer.
On September 27, 2024, the Board of Directors of the Company announced the appointment of Jeffrey Royal as the Chief Executive Officer of the Company.
On September 27, 2024, Michael Rost departed as Chief Executive Officer of Nicholas Financial, Inc. (the “Company”).
On September 26, 2024, the Board appointed Tara Comonte as Interim President and Chief Executive Officer, effective September 27, 2024, to serve until a permanent President and Chief Executive Officer is identified.
On September 26, 2024, WW International, Inc. (the “Company”) and Sima Sistani, the Company’s President and Chief Executive Officer, mutually agreed that Ms. Sistani would cease serving as the Company’s President and Chief Executive Officer, effective September 27, 2024.
On September 25, 2024, the Board of Directors of the Company (the “Board”) designated Amy Elazzouzi, the Company’s Vice President, Finance, as the Company’s interim principal financial officer and interim principal accounting officer, in each case, effective on the Transition Date, to serve in such roles during the pendency of the Company’s search for a new Chief Financial Officer.
On September 23, 2024, Julie Feder notified Aura Biosciences, Inc. (the “Company”) of her departure from her role at the Company as an employee and Chief Financial Officer, effective as of October 25, 2024 (the “Transition Date”).
On September 23, 2024, Terence Kohler, Chief Financial Officer of the Company, notified the Company of his resignation from his position, effective October 4, 2024 (the “Separation Date”), to pursue a new business opportunity.
the Board appointed Bradley G. Smith as the Company’s Chief Financial Officer and designated him an executive officer of the Company, effective September 29, 2024.
Mr. Lahanas will resign as the Company’s Chief Financial Officer effective September 28, 2024.
the Board appointed Nicholas Lahanas as the Company’s Chief Executive Officer and a member of the Board effective September 29, 2024.
Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he would depart the Company effective September 30, 2024, and will continue to serve as consultant to the Company for a period of nine months thereafter.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.